News Search Results
Jul 17, 2025, 05:00 ET Five-year Pharmacovigilance study by NTC confirms safety of fixed-dose eye drops for Post-cataract Surgery
"Pharmacovigilance on dexamethasone 1mg/mL + levofloxacin 5 mg/mL eye drops, solution: a five-year registry.", was conducted by experts in ophthalmology and drug safety.
More news about: NTC Srl
Jul 17, 2025, 05:00 ET Five-year Pharmacovigilance study by NTC confirms safety of fixed-dose eye drops for Post-cataract Surgery
"Pharmacovigilance on dexamethasone 1mg/mL + levofloxacin 5 mg/mL eye drops, solution: a five-year registry.", was conducted by experts in ophthalmology and drug safety.
More news about: NTC Srl
Jul 17, 2025, 00:00 ET Astellas Announces a Partnership with the "Korea Institute of Startup and Entrepreneurship Development", an Umbrella Organization of the "Ministry of SMEs and Startups", a Korean Government Agency, for the Operation of the "Partnership with Global Companies Program"
company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases
More news about: Astellas Pharma Inc.
Jul 16, 2025, 20:00 ET Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that Nature Medicine (IF: 58.7) has published the results of the Phase 1 clinical study of IBI343, an
More news about: Innovent Biologics
Jul 16, 2025, 03:14 ET TFS HealthScience Strengthens Global Ophthalmology Unit with Strategic Hires and Integrated Delivery Model
Marcia Swank, Vice President and Head of Ophthalmology, who has shaped the unit into a focused partner for companies developing therapies and devices for eye conditions. "In ophthalmology, every day counts for sponsors racing to innovate, and for patients waiting
More news about: TFS HealthScience
Jul 16, 2025, 02:56 ET TFS HealthScience Strengthens Global Ophthalmology Unit with Strategic Hires and Integrated Delivery Model
Marcia Swank, Vice President and Head of Ophthalmology, who has shaped the unit into a focused partner for companies developing therapies and devices for eye conditions. "In ophthalmology, every day counts for sponsors racing to innovate, and for patients waiting
More news about: TFS HealthScience
Jul 15, 2025, 10:35 ET ReFocus Eye Health Announces Acquisition of New View Eye Center, Expanding Access to Exceptional Vision Care
July 15, 2025 /PRNewswire/ -- ReFocus Eye Health, a leading regional network of ophthalmology in the Northeast and Mid-Atlantic, is pleased to announce the acquisition of
More news about: ReFocus Eye Health
Jul 15, 2025, 08:45 ET Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity
improving eye health outcomes across diverse populations. Supporting Research and Development in Ophthalmology: AI applications in retina image analysis contribute valuable data to the field of ophthalmology. This data aids in ongoing research, offering new insights into how retinal diseases develop and
More news about: MarketNewsUpdates
Jul 14, 2025, 17:31 ET MCR Therapies Market Set to Grow Rapidly Across the 7MM During the Forecast Period (2020-2034) with New Indications and Pipeline Advancements | DelveInsight
conventional treatments like corticosteroids and cyclosporine, PL9643 represents a novel, first-in-class melanocortin-based therapeutic approach in ophthalmology. Currently, PL9643 is in Phase III clinical development for moderate to severe dry eye disease, having demonstrated efficacy in the MELODY-1
More news about: DelveInsight Business Research, LLP
Jul 14, 2025, 07:27 ET Sun Pharma Announces Launch of LEQSELVI™ (deuruxolitinib) in the United States for the Treatment of Severe Alopecia Areata
company in the U.S. as well as global emerging markets. Sun Pharma's high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and oncodermatology and accounts for over 18% of company sales. The company's vertically integrated operations deliver high-quality medicines,
More news about: Sun Pharma
Jul 11, 2025, 10:30 ET Botulinum Toxins Market worth $15.7 billion by 2030 with 11.7% CAGR | MarketsandMarkets™
chronic migraines, dystonia, and spasticity. The use of Botox spans multiple medical fields, including neurology, dermatology, urology, ophthalmology, and rehabilitation medicine, contributing to its growing demand. Furthermore, Botox is supported by comprehensive training modules and patient
More news about: MarketsandMarkets
Jul 10, 2025, 10:02 ET Cincinnati Blepharoplasty Specialist Dr. Ginger Henson of AestheticEye Named 2025 Castle Connolly Top Doctor
Miami University and the University of Cincinnati College of Medicine. Dr. Henson completed her ophthalmology residency at the renowned Bascom Palmer Eye Institute in Miami, Florida, and further honed her expertise during
More news about: AestheticEye Oculoplastic Surgeons
Jul 10, 2025, 08:03 ET UMHS Launches UWorld-Backed Curriculum, Leading the Caribbean in Student-Focused Innovation
Recent residency matches include positions within highly competitive specialties such as Anesthesiology, Surgery, Ophthalmology, and Radiology. "Our integration of UWorld represents more than just a curriculum update," said President Ross. "It's part of a larger strategy
More news about: University of Medicine and Health Sciences, St. Kitts
Jul 10, 2025, 07:00 ET InMode to Report Second Quarter 2025 Financial Results and Hold Conference Call on July 30, Expects Q2 Revenue Between $95.4M-$95.5M, Decreases Full Year 2025 Revenue Guidance to be Between $365M-$375M
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com. Forward-Looking
More news about: InMode Ltd.
Jul 08, 2025, 12:45 ET ChristianaCare and Children's Hospital of Philadelphia Agree to Join Forces, Expand Access to World-Class Pediatric Care in Delaware
expertise in rare and complex diseases and a wide range of newborn and pediatric services, including surgery, cardiology, neurology, radiology, ophthalmology and genetics, as well as educational and research opportunities. As the collaboration grows, it will explore further opportunities to expand pediatric
More news about: Children's Hospital of Philadelphia
Jul 07, 2025, 22:08 ET Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)
monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific
More news about: Celltrion
Jul 07, 2025, 11:15 ET Procedure Trays Market Size Projected to Exceed USD 49.32 Billion by 2031 at a 10.2% CAGR, Driven by Increasing Surgical Procedures and Emphasis on Infection Control | The Insight Partners'
Market Segmentation Based on application, the procedure trays market is segmented into operating room, angiography, ophthalmology, and others. The operating room segment held the largest market share in 2024.By purchase mode, the procedure trays market is segmented
More news about: The Insight Partners
Jul 07, 2025, 08:00 ET ONE OF THE LARGEST MULTI-REGION HEALTHCARE SYSTEMS IN THE US EXPANDS ENTERPRISE IMAGING CLOUD SERVICE FROM SECTRA WITH PATHOLOGY TO LEVERAGE INTEGRATED DIAGNOSTICS IN CANCER CARE
of the healthcare provider's usage of Sectra's enterprise imaging solution as a cloud service, Sectra One Cloud. Together with the radiology and ophthalmology modules used today, the service now also equips pathologists with new tools and facilitates integrated diagnostics within cancer care.
More news about: Sectra
Jul 07, 2025, 03:00 ET One of the largest multi-region healthcare systems in the US expands enterprise imaging cloud service from Sectra with pathology to leverage integrated diagnostics in cancer care
of the healthcare provider's usage of Sectra's enterprise imaging solution as a cloud service, Sectra One Cloud. Together with the radiology and ophthalmology modules used today, the service now also equips pathologists with new tools and facilitates integrated diagnostics within cancer care.
More news about: Sectra
Jul 03, 2025, 04:00 ET Advancing Bone Health: European Commission Approves Biocon Biologics' Denosumab Biosimilars
Canada, and Japan. It has a pipeline of 20 biosimilar assets across diabetology, oncology, immunology, ophthalmology, bone health and other non-communicable diseases. The Company has many 'firsts' to its credit in the biosimilars industry. As part of its environmental,
More news about: Biocon Biologics
Jul 03, 2025, 01:25 ET Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)
1999;78(5):292-308. Li KJ, et al. Arthritis Res Ther. 2021;23(1):82. Albrecht K, et al. Z Rheumatol. 2024;83(Suppl 1):20-30. Chen JJ, et al. Ophthalmology. 2016;123(9):1999-2003. Donaldson L, et al. Pract Neurol. 2022;22(2):138-140. Hayreh SS, et al. Am J Ophthalmol. 1998;125(4):509-520. de Boysson
More news about: Novartis Pharmaceuticals Corporation
Jul 02, 2025, 10:44 ET Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats
patients' needs," said Dr. Ghassan Cordahi, MD, FACS, Assistant Clinical Professor, Faculty of Medicine, Department of Ophthalmology, Université de Montréal. "Aflibercept has been a cornerstone in managing retinal diseases, and the introduction of Aflivu offers a more affordable
More news about: Apotex Inc.
Jun 30, 2025, 12:29 ET Regenerative Medicine Market to Reach $45.66 Billion by 2032, Growing at a CAGR of 22.0% from 2025, Says Meticulous Research®
Analysis by Product (Gene Therapy, Stem Cell, Tissue Engineering) Application (Musculoskeletal, Cancer, Cardiovascular, Immunology, Dermatology, Ophthalmology) End User - Global Forecast to 2032," the Regenerative Medicine market is projected to reach $45.66 billion
More news about: Meticulous Market Research Pvt. Ltd.
Jun 30, 2025, 04:21 ET Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Ltd
Jun 30, 2025, 04:10 ET Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Ltd